AVR — AI Press-Release Analysis & Sentiment

French regulatory clearance allows patient recruitment to commence for the pivotal DurAVR® THV PARADIGM Trial, unlocking a major European market. (Timing: Patient recruitment in France is expected to commence soon, with ongoing trial results and milestones as future catalysts.)

Advancing patient enrollment, particularly the commencement of U.S. enrollment, in the pivotal PARADIGM Trial for the DurAVR THV System, along with CMS reimbursement for trial participants. These are critical steps towards potential commercialization. (Timing: Recruitment is ongoing with U.S. enrollment having recently commenced. Key trial results and commercial launch are expected over the medium-term (1-3 years).)

CMS reimbursement enables the pivotal PARADIGM trial to advance, a critical step towards commercializing the DurAVR Transcatheter Heart Valve by securing funding for patient procedures. (Timing: U.S. site activation for the trial is expected to accelerate now, with trial execution and potential results unfolding over the next 1-3 years.)